Dr. Jakubowiak on Phase I Daratumumab Regimens in Newly Diagnosed Multiple Myeloma

Andrzej Jakubowiak, MD, PhD
Published: Monday, Jun 12, 2017



Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, The University of Chicago Medicine, discusses a phase I study of daratumumab (Darzalex) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma.

Investigators believe progress is being made with some other novel regimens in multiple myeloma and able to get several patients to minimal residual disease (MRD)-negativity, Jakubowiak says. KRd, as a triplet, has emerged as an active regimen that has performed better against other therapies, he says. Additionally, KRd can be further improved by implementing transplant.

Rather than transplant, researchers sought to combine KRd with daratumumab, defined by Jakubowiak as one of the most promising agents in the field. Thus far, regimens explored with daratumumab have shown great promise, leading to the rationale for this study.


Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, The University of Chicago Medicine, discusses a phase I study of daratumumab (Darzalex) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma.

Investigators believe progress is being made with some other novel regimens in multiple myeloma and able to get several patients to minimal residual disease (MRD)-negativity, Jakubowiak says. KRd, as a triplet, has emerged as an active regimen that has performed better against other therapies, he says. Additionally, KRd can be further improved by implementing transplant.

Rather than transplant, researchers sought to combine KRd with daratumumab, defined by Jakubowiak as one of the most promising agents in the field. Thus far, regimens explored with daratumumab have shown great promise, leading to the rationale for this study.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x